

# DDL2017

## POSTERS

|   | Poster Board Nos |
|---|------------------|
| <p><b>An improved end-of-life performance for suspension pMDIs with Presspart plasma treated canisters</b></p> <p><b><u>Ameet Sule</u>, Abhay Singh, Dan Heyworth, Richard Turner, Andrew Newman</b></p> <p>H&amp;T Presspart Inhalation Product Technology Centre, Whitebirk Industrial Estate, Blackburn BB1 5RF, UK</p>  | <b>01</b>        |
| <p><b>Assessment of Potential Mouth/Throat Deposition and Lung Delivery of Suspension- and Solution-Formulated Inhaled Corticosteroid (ICS) Formulations Delivered by Pressurized Metered-Dose Inhaler (pMDI) without and with Valved Holding Chamber (VHC) Using an Anatomic Adult Upper Airway</b></p> <p><b><u>Jason A Suggett</u><sup>1</sup>, Mark W Nagel<sup>1</sup> &amp; Jolyon P Mitchell<sup>2</sup></b></p> <p><sup>1</sup>Trudell Medical international, 725 Third Street, London, Ontario, N5V 5G4, Canada<br/> <sup>2</sup>Jolyon Mitchell Inhaler Consulting Services Inc., 1154 St. Anthony Road, London, Ontario, N6H 2R1, Canada</p> | <b>02</b>        |
| <p><b>The Performance of Opt2Fill® Propellant Dispersible Tablet pMDI Formulations of Salbutamol Sulphate and Salbutamol Sulphate with Beclometasone Dipropionate in HFA 134a and HFA 152a.</b></p> <p><b><u>Simon Warren</u>, Cuong Tran, Chen Zheng, &amp; Glyn Taylor</b></p> <p>i2c Pharma Services, Cardiff Medicentre, Cardiff, CF14 4UJ, UK</p>  | <b>03</b>        |
| <p><b>Effect of poor inhalation-actuation coordination on the deposition of a pMDI drug used in current asthma and COPD therapy</b></p> <p><b><u>Árpád Farkas</u><sup>1</sup>, Attila Kerekes<sup>2</sup> &amp; Alpár Horváth<sup>3,4</sup></b></p> <p><sup>1</sup>Centre for Energy Research, Konkoly Thege M. 29-33, Budapest, 1121, Hungary<br/> <sup>2</sup>Wigner Research Centre for Physics, Konkoly Thege M. 29-33, Budapest, 1121, Hungary<br/> <sup>3</sup>Chiesi Hungary Ltd., Dunavirág u. 2, Budapest, 1138, Hungary<br/> <sup>4</sup>University of Debrecen, Nagyterdei körút 98, Debrecen, 4012, Hungary</p>                             | <b>04</b>        |
| <p><b>Characterisation of aerosols from solution-based pressurised metered dose inhalers (pMDIs) when delivered by PreciseInhale®</b></p> <p><b><u>Wachirun Terakosolphan</u><sup>1</sup>, Maria Malmlöf<sup>2</sup>, David Lewis<sup>3</sup> &amp; Ben Forbes<sup>1</sup></b></p> <p><sup>1</sup> Institute of Pharmaceutical Science, King's College London, SE1 9NH, UK<br/> <sup>2</sup> Inhalation Sciences, Hälsovägen 7, Stockholm, Sweden<br/> <sup>3</sup> Chiesi Limited, Chippenham, Wiltshire, SN14 0AB, UK</p>   | <b>05</b>        |
| <p><b>Optimising Mixing Process Parameters for an HFA pMDI Dual Suspension Product During Early Phase Product Development</b></p> <p><b><u>Sarah Dexter</u></b></p> <p>3M UK Ltd, Morley Street, Loughborough, Leics, LE11 1EP, UK</p>  | <b>06</b>        |

|   |                  |
|---|------------------|
|   |                  |
| <p><b>pMDI Uniformity of Delivered Dose Method Development using an Automated Dose Collection Apparatus</b></p> <p><b>Jim Clay &amp; Andy Cooper</b></p> <p>3M Drug Delivery Systems Ltd, Loughborough, Leicestershire LE11 1EP</p>   | <p><b>07</b></p> |
|   |                  |
| <p><b>Multi-Scale Modelling of the Formation of Adhesive Powder Mixtures for Inhalation</b></p> <p><b>Kyrre Thalberg<sup>1</sup>, Ingela Niklasson Björn<sup>1</sup>, Duy Nguyen<sup>1,2</sup> &amp; Anders Rasmuson<sup>2</sup></b></p> <p><sup>1</sup>AstraZeneca GOT, SE 431 83 Mölndal, Sweden<br/> <sup>2</sup>Chalmers University of Technology, SE 412 96 Gothenburg, Sweden</p>   | <p><b>08</b></p> |
|   |                  |
| <p><b>Evaluating the Impact of Operating Temperature and Humidity on Bipolar Charge Measurements using the Dekati BOLAR</b></p> <p><b>Cheng Pang<sup>1</sup>, Melanie Hamilton<sup>1</sup>, Justyna Nalepa-Grajcar<sup>1</sup>, David Prime<sup>1</sup>, Ed Taylor<sup>1</sup></b></p> <p><sup>1</sup>Drug Product Design &amp; Development, GlaxoSmithKline R&amp;D, Park Road, Ware, Hertfordshire, SG12 0DP, United Kingdom</p>  | <p><b>09</b></p> |
|   |                  |
| <p><b>Whistle training aid and smartphone App. provide objective data</b></p> <p><b>Mark Sanders<sup>1</sup> &amp; Elizabeth Crawford<sup>2</sup></b></p> <p><sup>1</sup>Clement Clarke International Limited, Edinburgh Way, Harlow, Essex, CM20 2TT, United Kingdom<br/> <sup>2</sup>Clin-e-cal Limited, Greenheys Business Centre, Pencroft Way, Manchester, M15 6JJ, United Kingdom</p>   | <p><b>10</b></p> |
|   |                  |
| <p><b>Determination of ability of a one-way valve to prevent bacterial transfer from patient to inhaler</b></p> <p><b>Mark Sanders<sup>1</sup>, Ron Bruin<sup>1</sup>, Richard Webb<sup>2</sup> &amp; Gillian Iredale<sup>2</sup></b></p> <p><sup>1</sup> Clement Clarke International Limited, Edinburgh Way, Harlow, Essex, CM20 2TT, United Kingdom<br/> <sup>2</sup>Industrial Microbiological Services Limited, Pale Lane, Hartley Wintney, Hampshire, RG27 8DH, United Kingdom</p>  | <p><b>11</b></p> |
|   |                  |
| <p><b>Acoustic methodology for measuring discharge rate, and predicting spray velocity effects on potential lung deposition</b></p> <p><b>Andy Cooper<sup>1</sup>, Chris Blatchford<sup>1</sup>, Barzin Gavtash<sup>2</sup></b></p> <p><sup>1</sup>3M Drug Delivery Systems Ltd, Loughborough, Leicestershire LE11 1EP<br/> <sup>2</sup>Wolfson School of Mechanical, Electrical and Manufacturing Engineering, Loughborough University, Loughborough, LE11 3TU, United Kingdom</p>   | <p><b>12</b></p> |
|   |                  |
| <p><b>Investigation of pulmonary drug permeability and tissue retention by computational analysis of rat ex vivo lung absorption profiles</b></p> <p><b>Johanna Eriksson<sup>1</sup>, Erik Sjögren<sup>1</sup>, Helena Thörn<sup>2</sup>, Katarina Rubin<sup>3</sup>, Per Bäckman<sup>2,4</sup> &amp; Hans Lennernäs<sup>1</sup></b></p> <p><sup>1</sup>Department of Pharmacy, Uppsala University, Uppsala, Sweden<br/> <sup>2</sup>Pharmaceutical Technology &amp; Development Inhalation, AstraZeneca-Gothenburg, Sweden<br/> <sup>3</sup>Respiratory, Inflammation &amp; Autoimmunity, Innovative Medicines and Early Development, AstraZeneca-Gothenburg, Sweden<br/> <sup>4</sup>Current address: Mylan Global Respiratory Group, Mylan Pharma UK Ltd., Kent CT13 9FF, UK</p> | <p><b>13</b></p> |
|   |                  |

|  |           |
|--|-----------|
| <p><b>Effect of Compressed Air Pressure on Particle Size Distribution During Aerosol Generation with Ultrafine TiO<sub>2</sub></b></p> <p><b><u>Maria Malmjöf</u><sup>1,2</sup>, <u>Mattias Nowenwik</u><sup>1</sup> &amp; <u>Per Gerde</u><sup>1,2</sup></b></p> <p><sup>1</sup>Inhalation Sciences, Hälsovägen 7-9, 141 57, Huddinge, Sweden<br/> <sup>2</sup>Institute of Environmental Medicine, Karolinska Institutet, Nobels Väg 13, 171 65, Solna, Sweden</p>   | <b>14</b> |
| <p><b>Respiratory irritants cause reversible up-regulation of pro-inflammatory cytokines on human nasal mucosa reconstituted <i>in vitro</i></b></p> <p><b><u>Faten Hussein</u><sup>1</sup>, <u>Bernadett Boda</u><sup>1</sup>, <u>Ludovic Wiszniewski</u><sup>1</sup>, <u>Song Huang</u><sup>1</sup> &amp; <u>Samuel Constant</u><sup>1</sup></b></p> <p><sup>1</sup>Epithelix Sàrl, 18 chemin des aulx, 1228 Plan-les-Ouates, Geneva, Switzerland</p>  | <b>15</b> |
| <p><b>Development of paclitaxel nanocrystal-based dry powder formulations for targeted therapy of lung tumours by inhalation</b></p> <p><b><u>Rémi Rosière</u><sup>1</sup>, <u>Selma Chraïbi</u><sup>1</sup>, <u>Sara Albasry</u><sup>1</sup>, <u>Marjorie Vermeersch</u><sup>2</sup>, <u>Karim Amighi</u><sup>1</sup> &amp; <u>Nathalie Wauthoz</u><sup>1</sup></b></p> <p><sup>1</sup>Laboratory of Pharmaceutics and Biopharmaceutics, Faculty of Pharmacy, Université libre de Bruxelles (ULB), Boulevard du Triomphe, B-1050 Brussels, Belgium,<br/> <sup>2</sup>Center for Microscopy and Molecular Imaging (CMMI), 8 Rue Adrienne Bolland, B-6041 Gosselies, Belgium</p>  | <b>16</b> |
| <p><b>In-Silico Lung Modeling Platform for Inhaled Drug Delivery in Beagle Dogs</b></p> <p><b><u>Antonio Cabal</u><sup>1</sup>, <u>Guido H. Jajamovich</u><sup>1</sup>, &amp; <u>Javad Heydari</u><sup>2</sup></b></p> <p><sup>1</sup>Merck &amp; Co., Inc., Kenilworth, NJ USA<br/> <sup>2</sup>Rensselaer Polytechnic Institute, 110 8th Street, Troy, NY 12180 USA</p>  | <b>17</b> |
| <p><b>Biorelevant and flexible dose deposition of drug substance powders and nebulised liquids onto filters and cell-cultures</b></p> <p><b><u>Frans Franek</u><sup>1</sup>, <u>Gabriella Yousef</u><sup>1</sup>, <u>Kinga Balogh Sivars</u><sup>2</sup>, <u>Helena Thörn</u><sup>1</sup>, <u>Rebecca Fransson</u><sup>3</sup> &amp; <u>Ulrika Tehler</u><sup>3</sup></b></p> <p>AstraZeneca R&amp;D, Pepparedsleden 1, Mölndal, 43183, Sweden<br/> <sup>1</sup>Pharmaceutical Technology &amp; Development Inhalation, Operations<br/> <sup>2</sup>Safety &amp; ADME Translational Sciences, IMED<br/> <sup>3</sup>Pharmaceutical Sciences, IMED</p>  | <b>18</b> |
| <p><b>IVIVC using <i>in silico</i> and PBPK methods for inhaled drug product development</b></p> <p><b><u>Viera Lukacova</u><sup>1</sup>, <u>Walter Woltosz</u><sup>1</sup>, <u>Beverley Patterson</u><sup>2</sup></b></p> <p><sup>1</sup>Simulations Plus, Inc., 42505 10<sup>th</sup> Street West, Lancaster, CA 93534, USA<br/> <sup>2</sup>formerly Actavis, UK</p>  | <b>19</b> |
| <p><b>Dissolution of Orally Inhaled Drugs using DissolvIt®: Influence of a Newly Designed Pre-Separator for Particle Collection</b></p> <p><b><u>Beatriz Noriega</u><sup>1,2</sup>, <u>Maria Malmjöf</u><sup>3,4</sup>, <u>Eunice Costa</u><sup>1</sup>, <u>M. Luisa Corvo</u><sup>2</sup>, <u>Per Gerde</u><sup>3,4</sup>, <u>Filipa M. Maia</u><sup>1</sup></b></p> <p><sup>1</sup>Hovione FarmaCiencia SA, Sete Casas, Loures, 2674-506, Portugal<br/> <sup>2</sup>Med.Ulisboa, Faculdade de Farmácia, Universidade de Lisboa, Avenida Prof. Gama Pinto, Lisboa, 1649-003, Portugal<br/> <sup>3</sup>Inhalation Sciences, Hälsovägen 7-9, 141 57, Huddinge, Sweden<br/> <sup>4</sup>Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden</p> | <b>20</b> |

|   |           |
|---|-----------|
|   |           |
| <p><b>The effect of impactor and impinger airflow on the air-liquid interface of tissue culture inserts</b></p> <p><b><u>G. Drummond</u><sup>1</sup>, D Murnane<sup>1</sup> &amp; V. Hutter<sup>1</sup></b></p> <p><sup>1</sup>University of Hertfordshire, College Lane, Hatfield, Hertfordshire, AL10 9AB, UK</p>   | <b>21</b> |
|   |           |
| <p><b>Investigating the impact of polarization on foamy macrophage induction by amiodarone in vitro</b></p> <p><b>E Hoffman, A Martin, DYS Chau, D Murnane, V Hutter</b></p> <p>Department of Pharmacy, Pharmacology and Postgraduate Medicine, School of Life and Medical Sciences, University of Hertfordshire, College Lane, Hatfield, AL10 9AB.</p>   | <b>22</b> |
|   |           |
| <p><b>Impact of blending parameters of the resonant acoustic mixer on the aerosol performance of ordered mixture formulations</b></p> <p><b><u>Alex Wimbush</u><sup>1</sup>, Kyrre Thalberg<sup>1</sup> &amp; Hanna Persson<sup>2</sup></b></p> <p><sup>1</sup>AstraZeneca, Pepparedsleden 1, Mölndal, 431 50, Sweden<br/> <sup>2</sup>AstraZeneca, Forskargatan 18, Södertälje, 151 85, Sweden</p>   | <b>23</b> |
|   |           |
| <p><b>A Triple Combination Anti-Tubercular Dry Powder Formulation for Treating Both Drug Susceptible and Multidrug Resistant Tuberculosis: Formulation and <i>In Vitro</i> Characterization</b></p> <p><b><u>Shyamal C. Das</u>, Claire Fan, Basanth Babu Eedara &amp; Shubhra Sinha</b></p> <p>School of Pharmacy, University of Otago, Adams Building, 18 Frederick Street, P.O. Box 56, Dunedin 9054, New Zealand</p>  | <b>24</b> |
|   |           |
| <p><b>Influence of storage conditions on ternary dry powder inhaler formulations</b></p> <p><b><u>Mats Hertel</u><sup>1</sup>, Eugen Schwarz<sup>2</sup>, Mirjam Kobler<sup>2</sup>, Sabine Hauptstein<sup>2</sup>, Hartwig Steckel<sup>3</sup> &amp; Regina Scherließ<sup>1</sup></b></p> <p><sup>1</sup> Department of Pharmaceutics and Biopharmaceutics, Kiel University, Grasweg 9a, 24118 Kiel, Germany<br/> <sup>2</sup> Meggle Excipients and Technology, Megglestr. 6 - 12, 83512 Wasserburg am Inn, Germany<br/> <sup>3</sup> Deva Holding AS, Istanbul, Turkey</p>   | <b>25</b> |
|   |           |
| <p><b>Impact of salbutamol sulphate particle properties on the tribocharging of inhalable mixtures</b></p> <p><b><u>J T Pinto</u><sup>1,2</sup>, S Zellnitz<sup>1</sup>, E Roblegg<sup>1,2</sup>, A Paudel<sup>1,3</sup></b></p> <p><sup>1</sup>Research Center Pharmaceutical Engineering GmbH, Inffeldgasse 13, Graz, 8010, Austria<br/> <sup>2</sup> Institute of Pharmaceutical Sciences, Pharmaceutical Technology and Biopharmacy, University of Graz, 8010 Graz, Austria<br/> <sup>3</sup> Institute for Process and Particle Engineering, Graz University of Technology, Inffeldgasse 13, Graz, 8010, Austria</p> | <b>26</b> |
|   |           |
| <p><b>Particle Interactions of Fluticasone Propionate and Salmeterol Xinafoate in Advair Diskus®</b></p> <p><b><u>Martin Jetzer</u><sup>1,2</sup>, Bradley Morriscal<sup>1</sup>, David Fergenson<sup>3</sup> &amp; Georgios Imanidis<sup>2</sup></b></p> <p><sup>1</sup>Novartis Pharma AG, Global Development, Novartis Campus, Lichtstrasse 35, Basel, 4056, Switzerland<br/> <sup>2</sup>University of Basel, Department of Pharmaceutical Sciences, Klingelbergstrasse 50, Basel, 4056, Switzerland<br/> <sup>3</sup>Livermore Instruments Inc., 2038 Livingston Street, Oakland CA, 94606, USA</p>                  | <b>27</b> |
|   |           |
| <p><b>The Mechanism of Magnesium Stearate to Modify Aerosol Performance in Dry Powder Inhaled Formulations</b></p> <p><b><u>Martin Jetzer</u><sup>1,2</sup>, Bradley Morriscal<sup>1</sup>, Marcel Schneider<sup>1</sup> &amp; Georgios Imanidis<sup>2</sup></b></p> <p><sup>1</sup>Novartis Pharma AG – Global Development, Novartis Campus, Lichtstrasse 35, Basel, 4056, Switzerland<br/> <sup>2</sup>University of Basel, Department of Pharmaceutical Sciences, Klingelbergstrasse 50, Basel, 4056, Switzerland</p>  | <b>28</b> |
|   |           |

|   |                  |
|---|------------------|
| <p><b>Evaluation of crystalline lactose-PEG composite particles as potential carriers for DPI formulations</b></p> <p><b><u>J T Pinto</u><sup>1,2</sup>, <u>S Zellnitz</u><sup>1</sup>, <u>T Guidi</u><sup>3</sup>, <u>L De Smet</u><sup>4</sup>, <u>E Roblegg</u><sup>1,2</sup>, <u>A Paudel</u><sup>1,5</sup></b></p> <p><sup>1</sup> Research Center Pharmaceutical Engineering GmbH, Inffeldgasse 13, Graz, 8010, Austria<br/> <sup>2</sup> Institute of Pharmaceutical Sciences, Pharmaceutical Technology and Biopharmacy, University of Graz, 8010 Graz, Austria<br/> <sup>3</sup> Chiesi Farmaceutici S.p.A., Largo F. Belloli 11/A, Parma, 43122, Italy<br/> <sup>4</sup> Xedev bvba, Industriepark Rosteyne 4, Zelzate, 9060, Belgium<br/> <sup>5</sup> Institute for Process and Particle Engineering, Graz University of Technology, Inffeldgasse 13, Graz, 8010, Austria</p> | <p><b>29</b></p> |
| <p><b>Formulating isoniazid for dry powder inhalation by spray drying</b></p> <p><b><u>I. Sibum</u>, <u>F. Grasmeijer</u>, <u>P. Hagedoorn</u> &amp; <u>H.W. Frijlink</u></b></p> <p>Department of Pharmaceutical Technology and Biopharmacy, Ant. Deusinglaan 1, Groningen, 9713 AV, the Netherlands</p>   | <p><b>30</b></p> |
| <p><b>Linking the structural properties of adhesive mixtures to their observed powder mechanics</b></p> <p><b><u>Jonas Rudén</u><sup>1</sup>, <u>Göran Frenning</u><sup>1</sup>, <u>Tobias Bramer</u><sup>2</sup>, <u>Kyrre Thalberg</u><sup>2</sup> &amp; <u>Göran Alderborn</u><sup>1</sup></b></p> <p><sup>1</sup>Department of Pharmacy, Uppsala University, Husargatan 3, Box 580, Uppsala, SE-751 23, Sweden<br/> <sup>2</sup>Pharmaceutical technology and development, AstraZeneca R&amp;D Gothenburg, Pepparedsleden 1, Mölndal, 431 83, Sweden</p>  | <p><b>31</b></p> |
| <p><b>A Novel Method Using a Smartphone to Capture and Analyse Patient Inspiratory Profiles</b></p> <p><b><u>Szer Ming Lee</u>, <u>Kian Min Lim</u>, <u>David Harris</u> &amp; <u>Phil Seeney</u></b></p> <p>PA Consulting Group, Cambridge Technology Centre, Melbourn, Royston SG8 6DP, United Kingdom</p>  | <p><b>32</b></p> |
| <p><b>Re-designing the colistimethate sodium Twincer<sup>®</sup> for large-scale production</b></p> <p><b><u>Floris Grasmeijer</u><sup>1,2</sup>, <u>Paul Hagedoorn</u><sup>1</sup> &amp; <u>Anne Haaije de Boer</u><sup>1</sup></b></p> <p><sup>1</sup>University of Groningen, Department of Pharmaceutical Technology and Biopharmacy, Antonius Deusinglaan 1, Groningen, 9713 AV, the Netherlands<br/> <sup>2</sup>PurelMS B.V., Ceintuurbaan Noord 152, Roden, 9301 NZ, the Netherlands</p>  | <p><b>33</b></p> |
| <p><b>Spray dried formulations for pulmonary delivery – challenges in filling, aerosol generation and delivery</b></p> <p><b><u>Regina Scherließ</u><sup>1</sup>, <u>Angelika Jüptner</u><sup>1</sup>, <u>Marie Hellfritsch</u><sup>1</sup>, <u>Camille Kaj</u><sup>2</sup>, <u>Aurore Vimont</u><sup>2</sup>, <u>Ségolène Sarrailh</u><sup>2</sup>, <u>Gerallt Williams</u><sup>2</sup></b></p> <p><sup>1</sup>Department of Pharmaceutics and Biopharmaceutics, Kiel University, Grasweg 9a, 24118 Kiel, Germany<br/> <sup>2</sup>Aptar Pharma, Route des Falaises, 27100 Le Vaudreuil, France</p>  | <p><b>34</b></p> |
| <p><b>What Could Be Learned From Glass Beads As Model Carrier System?</b></p> <p><b><u>Niklas Renner</u><sup>1</sup> <u>Hartwig Steckel</u>, <u>Nora Urbanetz</u> &amp; <u>Regina Scherließ</u><sup>1</sup></b></p> <p><sup>1</sup>Department of Pharmaceutics and Biopharmaceutics, Kiel University, Grasweg 9a, 24118 Kiel, Germany<br/> <sup>2</sup>Deva Holding A.S., Istanbul, Turkey <sup>3</sup>Daiichi Sankyo, Pfaffenhofen, Germany</p>  | <p><b>35</b></p> |

|   |           |
|---|-----------|
| <p><b>Multivariate Modelling to Support Control Strategy Definition of Ellipta™ Combination Inhaled Products</b></p> <p><b><u>Michelle Dawson</u><sup>1</sup>, Sandeep Sharma &amp; Simeone Zomer</b></p> <p><sup>1</sup>GlaxoSmithKline R&amp;D, Park Road, Ware, Herts, SG12 0DP, UK</p>  | <b>36</b> |
| <p><b>Coarse Lactose Particles as Dispersion Enhancers During Aerosolization of Dry Powder Formulations</b></p> <p><b>Edward Yost, Vibha Puri, and Ajit Narang</b></p> <p>Small Molecule Pharmaceutical Sciences, Genentech, Inc., One DNA Way, South San Francisco, CA, 94080, USA</p>   | <b>37</b> |
| <p><b>Investigating the microstructure of dry powder inhalers using orthogonal analytical approaches</b></p> <p><b><u>Gonçalo Farias</u><sup>1</sup>, William Ganley<sup>1</sup>, Debbie Huck-Jones<sup>2</sup>, Paul Kippax<sup>2</sup>, Jagdeep Shur<sup>1</sup> &amp; Robert Price<sup>1</sup></b></p> <p><sup>1</sup>Department of Pharmacy and Pharmacology, University of Bath, UK<br/> <sup>2</sup>Malvern Instruments Limited, Grovewood Road, Malvern, UK</p>  | <b>38</b> |
| <p><b>Impact of Capsule Type on the Aerodynamic Performances of a Fluticasone Propionate-based Dry Powder under Optimal and Suboptimal Inhalation Flowrates</b></p> <p><b><u>Nathalie Wauthoz</u><sup>1</sup>, Ismaël Hennia<sup>1</sup>, Susana Ecenarro<sup>2</sup> &amp; Karim Amighi<sup>1</sup></b></p> <p><sup>1</sup>Laboratory of Pharmaceutics and Biopharmaceutics, Université libre de Bruxelles (ULB), Boulevard du Triomphe CP207, Brussels 1050, Belgium<br/> <sup>2</sup>Qualicaps Europe S.A.U., Avenida Monte Valdelatas 4, Alcobendas 28108, Spain</p>  | <b>39</b> |
| <p><b>The Methacholine Challenge Test for Reversible Airways Disease Assessment: A Practical Guide on how to Interpret New 2017 ERS Guidelines</b></p> <p><b><u>Jason A Suggett</u><sup>1</sup>, Mark W Nagel<sup>1</sup> &amp; Jolyon P Mitchell<sup>2</sup></b></p> <p><sup>1</sup>Trudell Medical international, 725 Third Street, London, Ontario, N5V 5G4, Canada<br/> <sup>2</sup>Jolyon Mitchell Inhaler Consulting Services Inc., 1154 St. Anthony Road, London, Ontario, N6H 2R1, Canada</p>   | <b>40</b> |
| <p><b>Impact of Salbutamol Sulphate Particle Properties on Biological Effects in the Lung</b></p> <p><b><u>Sarah Zellnitz</u><sup>1</sup>, Lisa Zellnitz<sup>1</sup>, Eva Roblegg<sup>1,2</sup> &amp; Eleonore Fröhlich<sup>1,3</sup></b></p> <p><sup>1</sup> Research Center Pharmaceutical Engineering GmbH, Inffeldgasse 13, Graz, 8010, Austria<br/> <sup>2</sup> Institute of Pharmaceutical Sciences, Department of Pharmaceutical Technology, Karl-Franzens University of Graz, 8010, Austria<br/> <sup>3</sup> Center for Medical Research, Medical University of Graz, Stiftingtalstraße 24, Graz, 8010, Austria</p>   | <b>41</b> |
| <p><b>Pharmacokinetic Evaluation and Tolerability of Inhaled Dry Powder Levodopa in Parkinson's Disease Patients</b></p> <p><b><u>Marianne Luinstra</u><sup>1,2</sup>, A Wijnand F Rutgers<sup>3</sup>, Sebastiaan J Vroegop<sup>4</sup>, Anja Begeman<sup>1</sup>, Anne J Lexmond<sup>1</sup>, Floris Grasmeijer<sup>1</sup>, Paul Hagedoorn<sup>1</sup>, Anne H de Boer<sup>1</sup> &amp; Henderik W Frijlink<sup>1</sup></b></p> <p><sup>1</sup> University of Groningen, Pharmaceutical Technology and Biopharmacy, Antonius Deusinglaan 1, 9713 AV Groningen, NL<br/> <sup>2</sup> Martini Hospital, Clinical Pharmacy and Toxicology, Van Swietenplein 1, 9728 NT Groningen, NL<br/> <sup>3</sup> Martini Hospital, Neurology and Clinical Neurophysiology, Van Swietenplein 1, 9728 NT Groningen, NL<br/> <sup>4</sup> Martini Hospital, Pulmonary Diseases, Van Swietenplein 1, 9728 NT Groningen, NL</p> | <b>42</b> |

|  |           |
|--|-----------|
|  |           |
| <p><b>Combinational Approach for Advanced Understanding of a Low-Dose Capsule Filling Process for Inhalation Application</b></p> <p><b><u>Eva Faulhammer</u><sup>1</sup>, Sandra Stranzinger<sup>1,3</sup>, Vittorio Calzolari<sup>2</sup>, Stefano Biserni<sup>2</sup>, Peter Loidolt<sup>3</sup>, Amrit Paudel<sup>1,3</sup>, Johannes Khinast<sup>1,3</sup></b></p> <p><sup>1</sup>Research Center Pharmaceutical Engineering (RCPE), Inffeldgasse 13, Graz, 8010, Austria<br/> <sup>2</sup>MG2, Via del Savena 18, Pianoro BO, 40065, Italy<br/> <sup>3</sup>Technical University Graz – Institute of Process and Particle Engineering, Inffeldgasse 13, Graz, 8010 Austria</p>  | <b>43</b> |
| <p><b>Effect of Humidification System Choice on Aerosol Delivery during Mechanical Ventilation</b></p> <p><b><u>Gavin Bennett</u><sup>1</sup>, Sorcha Murphy<sup>1</sup>, Ian McDonnacha<sup>1</sup>, Mary Joyce<sup>1</sup>, Louise Sweeney<sup>1</sup> &amp; Ronan MacLoughlin<sup>1</sup></b></p> <p><sup>1</sup>Aerogen, IDA Business Park, Dangan, Galway, Ireland</p>  | <b>44</b> |
| <p><b>The Expression of TRPV1 in Airway Epithelium and its Role in Airway Hypersensitivity</b></p> <p><b><u>J. Xu</u><sup>1,2</sup>, M. Ghadiri<sup>1</sup>, B. McParland<sup>2</sup>, M.Svolos<sup>1</sup>, L.Moir<sup>1</sup>, F.Sanai<sup>1,2</sup>, D. Traini<sup>1</sup>, P.M.Young<sup>1</sup></b></p> <p><sup>1</sup>Woolcock Institute of Medical Research, 431 Glebe Point Road, Glebe, Sydney, 2037, Australia<br/> <sup>2</sup>The University of Sydney, Camperdown, Sydney, 2006, Australia</p>  | <b>45</b> |
| <p><b>Assessment of Aerosol Delivery to Adult and Paediatric Tracheostomised Patients during Weaning from Mechanical Ventilation</b></p> <p><b><u>Mary Joyce</u><sup>1</sup>, Sorcha Ní Mhurchú<sup>1</sup>, Gavin Bennett<sup>1</sup>, Ian MacDonnacha<sup>1</sup>, Louise Sweeney<sup>1</sup> &amp; Ronan MacLoughlin<sup>1</sup></b></p> <p><sup>1</sup>Aerogen, Galway Business Park, Dangan, Galway, H91 HE94, Ireland</p>  | <b>46</b> |
| <p><b>The Global Inhaler Effectiveness Score (GIES): A Novel Tool for Assessing and Ranking <i>in vitro</i> Properties and Patients Usability of Dry Powder Inhalers. Rationale and Methodology</b></p> <p><b><u>Francesca Buttinj</u><sup>1</sup>, Federico Lavorini<sup>2</sup>, Ruggero Bettini<sup>1</sup>, Søren E. Pedersen<sup>4</sup>, Richard P.N. Dekhuijzen<sup>5</sup>, Mark L. Levy<sup>6</sup> and Omar S. Usmani<sup>7</sup></b></p> <p><sup>1</sup>Food and Drug Department, University of Parma, IT<br/> <sup>2</sup>Careggi University Hospital, Florence, IT<br/> <sup>4</sup>Paediatric Research Unit, University of Southern Denmark, Kolding Hospital, DK<br/> <sup>5</sup>Department of Pulmonary Diseases, Radboud University Nijmegen Medical Centre, NL<br/> <sup>6</sup>Kenton Bridge Medical Centre, London, UK<br/> <sup>7</sup>Imperial College London and Royal Brompton Hospital, London, UK</p>   | <b>47</b> |
| <p><b>A Study to Investigate the Ability of Inhaled Amiodarone to Induce ‘Foamy’ Alveolar Macrophages in Male Wistar Han Rats</b></p> <p><b><u>Aateka Pate</u><sup>1,2</sup>, Ewelina Hoffman<sup>3</sup>, Doug Ball<sup>4</sup>, Jan Klapwijk<sup>5</sup>, Karen Cartwright<sup>5</sup>, Clive Page<sup>1</sup>, Lea Ann Dailey<sup>6</sup>, Ben Forbes<sup>2</sup></b></p> <p><sup>1</sup>Sackler Institute of Pulmonary Pharmacology, Faculty of Life Sciences &amp; Medicine, Franklin-Wilkins Building, King’s College London, 150 Stamford Street, London SE1 9NH, U.K<br/> <sup>2</sup>Institute of Pharmaceutical Science, King’s College London, Franklin-Wilkins Building, King’s College London, 150 Stamford Street, London SE1 9NH, UK<br/> <sup>3</sup>Centre for Topical Drug Delivery and Toxicology, School of Life and Medical Sciences, University of Hertfordshire, Hatfield, Herts, AL10 9AB, UK<br/> <sup>4</sup>Allergic Inflammation Discovery Performance Unit, GlaxoSmithKline, Gunnelswood Road, Stevenage, Herts, SG1 2NY, UK<br/> <sup>5</sup>Translational Medicine and Comparative Pathobiology, GlaxoSmithKline, Park Road, Ware, Hertfordshire, SG12 0DP, UK<br/> <sup>6</sup>Institute of Pharmaceutical Technology and Biopharmacy, Martin Luther University Halle-Wittenberg, Wolfgang-Langenbeck-Str. 4, 06108 Halle (Saale), Germany</p> | <b>48</b> |
|  |           |

|  |           |
|--|-----------|
| <p><b>Suitability of Used Impactors – Why the ‘Effective Diameter’ Criterion Needs the ‘Jet-to-Plate’ Criterion to Assure Measurement Capability in a Good Cascade Impactor Practice (GCIP) Environment</b></p> <p><b><u>Daryl L. Roberts</u><sup>1</sup>, &amp; Jolyon P. Mitchell<sup>2</sup></b></p> <p><sup>1</sup>Applied Particle Principles, LLC, 9194 Edison Street, Blaine, Minnesota, USA<br/> <sup>2</sup>Jolyon Mitchell Inhaler Consulting Services Inc., 1154 St. Anthony Road, London, Ontario, N6H 2R1, Canada</p>   | <b>49</b> |
| <p><b>Round robin of particle sizing method of a dry powder inhalation carrier</b></p> <p><b><u>David Stadermann</u><sup>1</sup>, Gerard Boswinkel<sup>2</sup>, Gerald Hebbink<sup>2</sup> &amp; Harry Peters<sup>2</sup></b></p> <p><sup>1</sup>David Stadermann Independent Consultant, Hirschbergstrasse 20, 80634 Munich, Germany<br/> <sup>2</sup>DFE Pharma, Needseweg 23, 7271AB Borculo, the Netherlands</p>   | <b>50</b> |
| <p><b>Stability of Formoterol as model for a reduction-sensitive material in blends for inhalation</b></p> <p><b><u>Nancy Rhein</u><sup>1</sup>, Gudrun Birk<sup>2</sup>, Ulrich Girreser<sup>3</sup>, Regina Scherließ<sup>1</sup></b></p> <p><sup>1</sup>Department of Pharmaceutics and Biopharmaceutics, Kiel University, Grasweg 9a, 24118 Kiel, Germany<br/> <sup>2</sup>Merck KGaA, Frankfurter Straße 250, 64293 Darmstadt, Germany<br/> <sup>3</sup>Department of Pharmaceutical/Medical Chemistry, Kiel University, Gutenbergstrasse 76, 24118 Kiel, Germany</p> | <b>51</b> |
| <p><b>Crystallisation of Beclomethasone Dipropionate from Supersaturated Solutions: The Impact of Solvent Properties on Crystalline APIs</b></p> <p><b><u>Cordula Weiss</u><sup>1</sup>, Peter McLoughlin<sup>1</sup>, Panagiotis Manesiotis<sup>2</sup>, Peter Nockemann<sup>2</sup> &amp; Helen Cathcart<sup>1</sup></b></p> <p><sup>1</sup>Waterford Institute of Technology, Cork Road, Waterford, X91 K0EK, Ireland<br/> <sup>2</sup>Queen’s University Belfast, University Road, Belfast, BT7 1NN, Northern Ireland, UK</p>  | <b>52</b> |
| <p><b>An innovative route to measure BET specific surface area (SSA) of powder device inhaler (DPI) carriers</b></p> <p><b><u>Antonio Salituro</u><sup>1</sup>, Glen Guerneur<sup>1</sup></b></p> <p><sup>1</sup> LGC CMC Analytical Services, Discovery Park House Ramsgate Road Sandwich Kent CT13 9ND UK</p>  | <b>53</b> |
| <p><b>Dual Automated Approach for Sizing and Characterizing Budesonide In Suspension</b></p> <p><b><u>Emily Landsperger</u><sup>1</sup>, Angela Flowers<sup>1</sup> &amp; David Exline<sup>1</sup></b></p> <p><sup>1</sup>Gateway Analytical, 2009 Kramer Road, Gibsonia, PA / 15044, USA</p>  | <b>54</b> |
| <p><b>API Influence &amp; Stability Assessment of dual API combination of spray dried composite particles</b></p> <p><b><u>Maria Palha</u><sup>1</sup>, Sofia Silva<sup>1</sup>, Raquel Barros<sup>1</sup>, Cláudia Moura<sup>1</sup>, Sara Cardoso<sup>1</sup> &amp; Eunice Costa<sup>1</sup></b></p> <p><sup>1</sup>Hovione FarmaCiencia SA, Sete Casas, 2674-506 Loures, Portugal</p>   | <b>55</b> |
| <p><b>Effect of throat models and representative deposition profiles on the performance of carrier-based formulations</b></p> <p><b><u>Sofia Silva</u><sup>1</sup>, Maria Palha<sup>1</sup>, Andreia Costa<sup>1</sup>, Ruben Chaves<sup>1</sup> &amp; Eunice Costa<sup>1</sup></b></p> <p><sup>1</sup>Hovione FarmaCiencia SA, Sete Casas, 2674-506 Loures, Portugal</p>  | <b>56</b> |



|  |           |
|--|-----------|
|  |           |
| <p><b>Effect of Air Jet Micronization on Particle Properties and the Correlation of Interparticle Interactions by Atomic Force Microscopy with Surface Forces by Inverse Gas Chromatography</b></p> <p><b><u>Vibha Puri</u><sup>1</sup>, Jagdeep Shur<sup>2</sup>, Robert Price<sup>2</sup>, Andreas Stumpf<sup>1</sup>, &amp; Ajit Narang<sup>1</sup></b></p> <p><sup>1</sup>Small Molecule Pharmaceutical Sciences, Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080, USA<br/> <sup>2</sup>Nanopharm Ltd., Cavendish House, Newport NP10 8FY, UK</p>  | <b>57</b> |
|  |           |
| <p><b>Amorphous content determination by Solution Calorimetry: A Quality Perspective</b></p> <p><b><u>Mridul Majumder</u></b></p> <p>M2M Pharmaceuticals Ltd., Science &amp; Technology Centre, University of Reading, Reading RG6 6BZ, UK</p>   | <b>58</b> |
|  |           |
| <p><b>Comparison of TSI/Transwell<sup>®</sup> and NGI/Rotating Paddle as dissolution methods for orally inhaled products</b></p> <p><b><u>Mireille Hassoun</u><sup>1</sup>, Mark Copley<sup>2</sup>, Paul G. Royall<sup>1</sup>, Mark Parry<sup>3</sup>, Ben Forbes<sup>1</sup></b></p> <p><sup>1</sup>Institute of Pharmaceutical Science, King's College London, SE1 9NH, UK<br/> <sup>2</sup>Copley Scientific Limited, Colwick, Nottingham, NG4 2JY, UK<br/> <sup>3</sup>Intertek-Melbourn Scientific Limited, Saxon Way, Melbourn, SG8 6DN, UK</p>  | <b>59</b> |
|  |           |
| <p><b><i>Poster Withdrawn</i></b></p>  | <b>60</b> |
| <p><b>Outcome of a Questionnaire within European Pharmaceutical Aerosol Group (EPAG) Companies Concerning the Implementation of the Abbreviated Impactor Measurement (AIM) Concept for the Assessment of Orally Inhaled Product (OIP) Aerosol Aerodynamic Particle Size Properties</b></p> <p><b><u>Hamilton M</u><sup>1</sup>, Blatchford CB<sup>2</sup>, Mitchell JP<sup>3</sup> &amp; Versteeg HK<sup>4</sup></b></p> <p><sup>1</sup>GSK, David Jack Centre for R&amp;D, Park Road, Ware, Hertfordshire, SG12 0DP, United Kingdom<br/> <sup>2</sup>3M United Kingdom PLC, 1, Morley Street, Loughborough, Leicestershire, LE11 1EP UK<br/> <sup>3</sup>Jolyon Mitchell Inhaler Consulting Services Inc., 1154 St Anthony Road, London, Ontario, N6H 2R1, Canada<br/> <sup>4</sup>Wolfson School of Mechanical, Electrical &amp; Manufacturing Engineering, Loughborough University, Loughborough, LE11 3TU, Leics, U.K.</p> | <b>61</b> |
|  |           |
| <p><b>Passive Mesh, Active Mesh and Ultrasonic Nebulizers – Ability to Deliver a Budesonide Suspension</b></p> <p><b>L Slator, Y Degtyareva, R Potter &amp; <u>RHM Hatley</u></b></p> <p>Respironics Respiratory Drug Delivery (UK) Ltd, a business of Philips Electronics UK Limited, Chichester, West Sussex, UK</p>   | <b>62</b> |
|  |           |
| <p><b>Deposition modelling of inhaled aclidinium and budesonide and comparison to gamma scintigraphy measurement</b></p> <p><b><u>Helena Thörn</u><sup>1</sup>, Thomas Lööf<sup>1</sup>, Gunilla Petersson<sup>1</sup>, Frans Franek<sup>1</sup>, Rebecca Fransson<sup>2</sup> &amp; Ulrika Tehler<sup>2</sup></b></p> <p><sup>1</sup>AstraZeneca R&amp;D, Pharmaceutical Technology &amp; Development Inhalation, Pepparedsleden 1, Mölndal, 43183, Sweden<br/> <sup>2</sup>AstraZeneca R&amp;D, Pharmaceutical Sciences, Pepparedsleden 1, Mölndal, 43183, Sweden</p>  | <b>63</b> |
|  |           |
| <p><b>Aerosol characterization of nebulised liposomes co-loaded with erlotinib and genistein</b></p> <p><b>Nattika <u>Nimmano</u><sup>1</sup>, Satynarayana Somavarapu<sup>1</sup> &amp; Kevin M.G Taylor<sup>1</sup></b></p> <p><sup>1</sup>Department of Pharmaceutics, UCL School of Pharmacy, 29-39 Brunswick Square, London, WC1N 1AX, United Kingdom</p>   | <b>64</b> |
|  |           |

|   |           |
|---|-----------|
|   |           |
| <p><b>Ultrasonic versus Two-Fluid Nozzle in a Spray Drying Process: A Comparative Study for the Production of Dry Powder Inhaler Formulations for Biopharmaceutical Delivery</b></p> <p><b><u>Diana A. Fernandes</u><sup>1,2</sup>, Raquel Barros<sup>1</sup>, Cláudia Moura<sup>1</sup>, João Pereira<sup>1</sup>, M. Luísa Corvo<sup>2</sup> &amp; Eunice Costa<sup>1</sup></b></p> <p><sup>1</sup>Hovione SA, Loures, 2074-506, Portugal<br/> <sup>2</sup>Research Institute for Medicines (iMed.Ulisboa), Faculdade de Farmácia, Universidade de Lisboa, Lisboa, 1649-003, Portugal</p> | <b>65</b> |
|   |           |
| <p><b>Comparison of Aerosol Delivery Efficacy by A Specially Designed T-adaptor with Vibrating Mesh Nebulizer and Existing Products in Adult Mechanical Ventilator</b></p> <p><b><u>Chia-Chen Huang</u><sup>1</sup>, Hsiang-Ling Chen<sup>1</sup>, Chi-Shan Hung<sup>1</sup>, Eric Y.T. Chen<sup>1</sup>, Hui-Ling Lin<sup>2</sup></b></p> <p><sup>1</sup>MicroBase Technology Corp, 756, Jiadong Road, Bade, Taoyuan, 33464, Taiwan<br/> <sup>2</sup>Chang Gung University, 261, Wenhua 1st Road, Guishan, Taoyuan, 3302, Taiwan</p>   | <b>66</b> |
|   |           |
| <p><b>Delivery of a Budesonide Suspension Formulation from Mesh vs Jet Nebulizers under Simulated Pediatric and Adult Breathing Patterns</b></p> <p><b><u>Lois Slator</u><sup>1</sup>, Natalie Cooper-Rayner<sup>1</sup>, Lucy E Hardaker<sup>1</sup>, Dirk von Hollen<sup>2</sup> &amp; John N Pritchard<sup>1</sup></b></p> <p><sup>1</sup> Respiroics Respiratory Drug Delivery (UK) Ltd, a business of Philips Electronics UK Limited, Chichester, West Sussex, UK<br/> <sup>2</sup> Respiroics, Inc., a Philips Healthcare Company, Murrysville, PA, USA</p>                           | <b>67</b> |
|   |           |
| <p><b>Consistency of Aerosol Delivery across High Flow Therapy Systems</b></p> <p><b><u>Gavin Bennett</u>, Mary Joyce, Sorcha Murphy, Ian McDonnacha, Louise Sweeney &amp; Ronan MacLoughlin</b></p> <p>Aerogen, IDA Business Park, Dangan, Galway, Ireland</p>   | <b>68</b> |
|   |           |
| <p><b>Development of a novel powder formulation for treatment of idiopathic pulmonary fibrosis</b></p> <p><b><u>Wayne Morley</u><sup>1</sup>, <u>Irene Parisini</u><sup>1</sup>, Martina Larini<sup>1</sup>, Arnaud Fillius<sup>1</sup>, Paola Zarantonello<sup>1</sup> Lise Gravelle<sup>2</sup> &amp; Anders Pedersen<sup>2</sup></b></p> <p><sup>1</sup>Aptuit S.r.l, Via Alexander Fleming 4, Verona, 37135, Italy<br/> <sup>2</sup>Galecto Biotech AB, Cobis Science Park, Ole Maaloes Vej 3, Copenhagen, DK-2200, Denmark</p>   | <b>69</b> |
|   |           |
| <p><b>Assessment of the feasibility of mouthpiece-mediated aerosol delivery during high flow nasal therapy.</b></p> <p><b><u>Ian MacDonnacha</u>, Gavin Bennett, Sorcha Murphy, Mary Joyce, Louise Sweeney &amp; Ronan MacLoughlin</b></p> <p>Aerogen, Galway Business Park, Dangan, Galway, Ireland</p>  | <b>70</b> |
|   |           |
| <p><b>Formulation, In Vitro And In-Vivo Analysis Of A Spray-Dried Topotecan Inhalation Powder</b></p> <p><b><u>Michael Burke</u><sup>1</sup>, Devon Dubose<sup>1</sup>, David Lyon<sup>1</sup>, Ramesh Chand<sup>2</sup>, Mathewos Tessema<sup>2</sup>, &amp; Philip Kuehl<sup>2</sup></b></p> <p><sup>1</sup>Capsgel, a Lonza Company, 64550 Research Rd, Bend, OR, 97701, USA<br/> <sup>2</sup> Lovelace Biomedical, 2425 Ridgcrest Drive. SE, Albuquerque, NM, 87108, USA</p>  | <b>71</b> |
|   |           |

|   |           |
|---|-----------|
|   |           |
| <p><b>Erlotinib-Fisetin-SBE-<math>\beta</math>-CD Complex for Pulmonary Delivery as an Improved Treatment for Non-small Cell Lung Cancer (NSCLC)</b></p> <p><b><u>Noratigah Mohtar</u><sup>1,2</sup>, Kevin M. G. Taylor<sup>1</sup> &amp; Satyanarayana Somavarapu<sup>1</sup></b></p> <p><sup>1</sup>Department of Pharmaceutics, UCL School of Pharmacy, 29-39 Brunswick Square, London WC1N 1AX, United Kingdom<br/> <sup>2</sup>School of Pharmaceutical Sciences, Universiti Sains Malaysia, 11800 Pulau Pinang, Malaysia</p>   | <b>72</b> |
| <p><b>Nano-in-microparticles for dry powder vaccination – possible for nasal application?</b></p> <p><b><u>Judith Heidland</u> &amp; Regina Scherließ</b></p> <p>Department of Pharmaceutics and Biopharmaceutics, Kiel University, Grasweg 9a, 24118 Kiel, Germany</p>   | <b>73</b> |
| <p><b>Preparation and characterization of siRNA-containing microparticles intended for inhalation with mannitol and albumin using spray drying technique</b></p> <p><b><u>Michael Y.T. Chow</u><sup>1</sup>, Suki S.K. Leung<sup>1,2</sup> &amp; Jenny K.W. Lam<sup>1</sup></b></p> <p><sup>1</sup>Department of Pharmacology &amp; Pharmacy, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong<br/> <sup>2</sup>School of Pharmacy, University College London, United Kingdom</p>  | <b>74</b> |
| <p><b>Konjac glucomannan microparticles for antitubercular drug delivery by inhalation</b></p> <p><b><u>Filipa Guerreiro</u><sup>1,2</sup>, Ana M Rosa da Costa<sup>3</sup>, Maria Leonor Faleiro<sup>1</sup> &amp; Ana Grenha<sup>1,2</sup></b></p> <p><sup>1</sup>CBMR – Centre for Biomedical Research, Drug Delivery Laboratory, University of Algarve, Campus de Gambelas, Faro, 8005-139, Portugal<br/> <sup>2</sup>CCMAR – Centre of Marine Sciences, University of Algarve, Campus de Gambelas, Faro, 8005-139, Portugal<br/> <sup>3</sup>Algarve Chemistry Research Centre (CIQA) and Department of Chemistry and Pharmacy, Faculty of Sciences and Technology, University of Algarve, Campus de Gambelas, 8005-139 Faro, Portugal</p> | <b>75</b> |
| <p><b>Preparation of influenza vaccine antigen powder that can withstand exposure to humid conditions</b></p> <p><b><u>Shogo Nakamura</u><sup>1</sup>, Mitsuhide Tanimoto<sup>1</sup>, Kaori Shinoda<sup>2</sup>, Kazuhiro Inoue<sup>1</sup>, Shuichi Yada<sup>1</sup> &amp; Shuichi Ando<sup>1</sup></b></p> <p>School of Pharmacy, University of Otago, Adams Building, 18 Frederick Street, P.O. Box 56, Dunedin 9054, New Zealand</p>   | <b>76</b> |
| <p><b>A study of Formulation and Delivery Device-Related Effects on In Vitro Performance of Nasal Sprays</b></p> <p><b><u>Jernej Grmas</u><sup>1</sup>, Badre Hammond<sup>2</sup>, Rade Injac<sup>1</sup>, Rok Dreu<sup>3</sup>, Gerallt Williams<sup>2</sup></b></p> <p>1 Lek Pharmaceuticals d.d., Ljubljana, Slovenia<br/> 2 Aptar Pharma, Le Vaudreuil, 27100, France<br/> 3 Faculty of Pharmacy, University of Ljubljana, Ljubljana, Slovenia</p>  | <b>77</b> |
| <p><b>Effective gene silencing effect mediated by the KL4/siRNA complexes in lung epithelial cells through clathrin-dependent endocytosis</b></p> <p><b><u>Yingshan Qiu</u>, Michael Y.T. Chow &amp; Jenny K.W. Lam</b></p> <p>Department of Pharmacology &amp; Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, 21 Sassoon Road, Pokfulam, Hong Kong</p>  | <b>78</b> |
|   |           |

|   |                  |
|---|------------------|
|   |                  |
| <p><b>Inhaled Pneumococcal Vaccination Method using Aerosolisation in a Paediatric Lamb Model</b></p> <p><b><u>Anushi E Rajapaksa</u><sup>1,2,4,6</sup>, <u>Anne Balloch</u><sup>1</sup>, <u>Paul Licciardi</u><sup>1,2</sup>, <u>Robert J. Bischof</u><sup>3</sup>, <u>Christina Cortez-Jugo</u><sup>2</sup>, <u>Magdy Sourial</u><sup>4</sup>, <u>Eileen Dunne</u><sup>1</sup>, <u>David Piedrafita</u><sup>5</sup>, <u>Kim Mulholland</u><sup>1</sup> and <u>David G Tingay</u><sup>1,2,4,6</sup></b></p> <p><sup>1</sup>Murdoch Childrens Research Institute, Melbourne, VIC Australia<br/> <sup>2</sup>University of Melbourne, Melbourne, Australia<br/> <sup>3</sup>The Ritchie Centre, Hudson Institute of Medical Research Melbourne, Australia<br/> <sup>4</sup>Royal Children's Hospital, Melbourne, Australia<br/> <sup>5</sup>Federation University, Melbourne, Australia<br/> <sup>6</sup>Royal Women's Hospital, Melbourne, Australia</p>  | <p><b>79</b></p> |
| <p><b>Development of a synthetic human lung fluid simulant for applications in inhalation biopharmaceutics</b></p> <p><b><u>Mireille Hassoun</u><sup>1</sup>, <u>Paul G. Royall</u><sup>1</sup>, <u>Richard D. Harvey</u><sup>2</sup>, <u>Mark Parry</u><sup>3</sup>, <u>Ben Forbes</u><sup>1</sup></b></p> <p><sup>1</sup>Institute of Pharmaceutical Science, King's College London, SE1 9NH, UK<br/> <sup>2</sup>Institute of Pharmacy, Martin-Luther-Universität Halle-Wittenberg, 06108 Halle (Saale), Germany<br/> <sup>3</sup>Intertek-Melbourn Scientific Limited, Saxon Way, Melbourn, SG8 6DN, UK</p>   | <p><b>80</b></p> |
| <p><b>Beclomethasone dipropionate Transport and Metabolism in EpiAirway™ Cell Layers</b></p> <p><b><u>Precious Akhmemokhan</u>, <u>Chris Grainger</u> &amp; <u>Ben Forbes</u></b></p> <p>Institute of Pharmaceutical Science, King's College London, SE1 9NH, UK</p>  | <p><b>81</b></p> |
| <p><b>Investigating orthogonal in vitro analytical approaches to demonstrate bioequivalence of nasal suspension formulations</b></p> <p><b><u>Gonçalo Farias</u><sup>1</sup>, <u>Robert Price</u><sup>1</sup>, <u>Debbie Huck-Jones</u><sup>2</sup>, &amp; <u>Jagdeep Shur</u><sup>2</sup></b></p> <p><sup>1</sup>Department of Pharmacy and Pharmacology, University of Bath, UK.<br/> <sup>2</sup>Malvern Instruments Limited, Grovewood Road, Malvern, UK</p>  | <p><b>82</b></p> |
| <p><b>THE PAT BURNELL NEW INVESTIGATOR AWARD FINALISTS</b></p>  |                  |
| <p><b>Further studies on the Drug Deposition Mechanisms of Surface-treated pMDI Canisters</b></p> <p><b><u>A. Skemperi</u><sup>1</sup>, <u>D. Worrall</u><sup>1</sup>, <u>G. Critchlow</u><sup>2</sup>, <u>P. Jinks</u><sup>3</sup></b></p> <p><sup>1</sup>Chemistry Department, Loughborough University, Loughborough, Leicestershire, UK<br/> <sup>2</sup>Materials Department, Loughborough University, Loughborough, Leicestershire, UK<br/> <sup>3</sup>3M Drug Delivery Systems, Loughborough, Leicestershire, UK</p>   | <p><b>83</b></p> |
| <p><b>Loading, release and activity of inhalable benzothiazinone-loaded human albumin nanocarriers for anti-tuberculosis therapy</b></p> <p><b><u>Ayasha Patel</u><sup>1</sup>, <u>Natalja Redinger</u><sup>4</sup>, <u>Adrian Richter</u><sup>2</sup>, <u>Arcadia Woods</u><sup>1</sup>, <u>Peter Imming</u><sup>2</sup>, <u>Ulrich E. Schaible</u><sup>4,5</sup>, <u>Nick Childerhouse</u><sup>3</sup>, <u>Ben Forbes</u><sup>1</sup> and <u>Lea Ann Dailey</u><sup>2</sup></b></p> <p><sup>1</sup>Institute of Pharmaceutical Science, King's College London, 150 Stamford Street, SE1 9NH, United Kingdom<br/> <sup>2</sup>Department of Pharmacy, Martin Luther University of Halle-Wittenberg, Wolfgang-Langenbeck-Str.4, 06120 Halle, Germany<br/> <sup>3</sup>Vectura Group plc, One Prospect West, Chippenham, Wiltshire, SN14 6FH, United Kingdom<br/> <sup>4</sup>Leibniz Center for Medicine &amp; Biosciences, Priority Area Infections, Dept. Cellular Microbiology, Parkallee 1, 23845 Borstel, Germany<br/> <sup>5</sup>German Center for Infection Research, TTU TB, Parkallee 1, 23845 Borstel, Germany</p> | <p><b>84</b></p> |

|  |           |
|--|-----------|
|  |           |
| <p><b>Cocrystal Approach to Reduce the Aqueous Solubility and Dissolution Rate for Improved Residence Time of an Anti-Tubercular Drug in the Lungs</b></p> <p><b><u>Basanth Babu Eedara</u>, Ian G. Tucker &amp; Shyamal C. Das</b></p> <p>School of Pharmacy, University of Otago, Adams Building, 18 Frederick Street, P.O. Box 56, Dunedin 9054, New Zealand</p>  | <b>85</b> |
|  |           |
| <p><b>Identification of contaminants on lactose using Ultrasound Acoustic-AFM. Impact on the interactions drug-carrier</b></p> <p><b><u>Cedric Thomas</u><sup>1</sup>, N. Pocholle<sup>1</sup>, E. Bourillot<sup>1</sup>, A. Kervinio<sup>2</sup>, L. Kerriou<sup>2</sup>, V. Gamberre<sup>2</sup>, C. Andrès<sup>1</sup>, E. Lesniewska<sup>1</sup></b></p> <p><sup>1</sup>ICB UMR CNRS 6303, Univ. Bourgogne Franche-Comté, Dijon, France<br/> <sup>2</sup>Armor Pharma, Armor Proteines SAS, Saint Brice-en-Cogles, France</p>  | <b>86</b> |
|  |           |
| <p><b>Characterisation of a Human Nasal Spray for Nose to Brain Delivery of Insulin</b></p> <p><b><u>Jed Wingrove</u><sup>1</sup>, Magda Swedrowska<sup>2</sup>, Mark Parry<sup>3</sup>, Mervin Ramjeeawon<sup>3</sup>, David Taylor<sup>2</sup>, Gregoire Gauthier<sup>4</sup>, Fernando Zelaya<sup>1</sup> &amp; Ben Forbes<sup>2</sup></b></p> <p><sup>1</sup>King's College London, Institute of Psychiatry, Psychology &amp; Neuroscience, London SE5 8AF, UK<br/> <sup>2</sup>King's College London, Institute of Pharmaceutical Science, London SE1 9NH, UK<br/> <sup>3</sup>Intertek-Melbourn, Melbourn SG8 6DN, UK<br/> <sup>4</sup>Nemera, La Verpillière 38292, France</p>  | <b>87</b> |
|  |           |
| <p><b>Pulmonary dry powders containing a vaccine against <i>Human papillomavirus</i></b></p> <p><b><u>Irene Rossi</u><sup>1</sup>, Francesca Buttini<sup>1</sup>, Fabio Sonvico<sup>1</sup>, Gloria Spagnoli<sup>2</sup>, Davide Cavazzini<sup>2</sup>, Angelo Bolchi<sup>2</sup>, Fabio Stellari<sup>3</sup>, Simone Ottonello<sup>2</sup>, Ruggero Bettini<sup>1</sup></b></p> <p><sup>1</sup>Food and Drug Department, University of Parma, Parma, Parco Area delle Scienze 27/A, 43124, Italy<br/> <sup>2</sup>Department of Chemistry, Life Sciences and Environmental Sustainability, University of Parma, Parma, Parco Area delle Scienze 11/A, 43124, Italy<br/> <sup>3</sup>Chiesi Farmaceutici S.p.A., Parma, Largo Belloli 11/A, 43122, Italy</p> | <b>88</b> |
|  |           |